Search for: "Mylan LLC" Results 81 - 100 of 266
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
25 Jul 2008, 11:56 pm
On April 25, 2008, Actavis Totowa LLC, the U.S. manufacturing division of the generic pharmaceutical company Actavis Group, voluntarily initiated a Class I nationwide recall of Digitek oral tablets of all strengths. [read post]
26 Feb 2014, 5:37 pm
  Procedural HistoryPlaintiff GlaxoSmithKline LLC (“GSK”) sued Banner Pharmacaps, Inc., Impax Laboratories, Inc., Roxane Laboratories, Inc., Mylan Inc., Mylan Pharmaceuticals, Inc., and Watson Laboratories, Inc. [read post]
18 Dec 2009, 9:59 am by Karen E. Keller
Mylan Pharmaceuticals Inc., Mylan, Inc., Matrix Laboratories Ltd. and Matrix Laboratories Inc. [read post]
14 Dec 2021, 9:57 am by Dennis Crouch
VLSI Technology LLC (Follow-on case to Mylan v. [read post]
26 Sep 2008, 7:23 pm
At the time of the JPMDL hearing in late July 2008 concerning the issue of whether a federal court Digitek MDL was necessary, there were at least 60 lawsuits which had been filed against Actavis Totowa, LLC and Mylan Pharmaceuticals, Inc., as well as numerous other corporate entities related to Acatavis and Mylan. [read post]
1 Mar 2013, 6:28 am by Gene Quinn
Also on November 8, Research Affiliates, LLC and WisdomTree Investments, Inc. [read post]
30 Jun 2014, 10:28 am
.; Amneal Pharmaceuticals LLC; Amneal Pharmaceuticals of New York, LLC; Amneal Pharmaceuticals Co. [read post]
18 Feb 2020, 4:00 am by Martin Kratz
In Seedlings Life Science Ventures, LLC v. [read post]
2 May 2024, 8:03 am by Melissa Tremblay
 Notably, their clients’ cases resulted in the largest government FCA settlements in 2017 (Mylan), 2018 (AmerisourceBergen), and 2022 (Mallinckrodt). [read post]
The following consumer protection actions made headlines this week: Mylan Reaches $465 Million Settlement Over Medicaid Classification On October 7, 2016, Mylan Inc. announced that it had agreed to pay $465 million to resolve a DOJ investigation into Mylan’s classification of EpiPen as a generic drug that resulted in Medicaid and Medicare receiving a significantly smaller rebate on every prescription since 2007. [read post]